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Treatment of Sheep Steroid–Induced Ocular
Hypertension with a Glucocorticoid-Inducible MMP1
Gene Therapy Virus
Rosana Gerometta,1 Maria-Grazia Spiga,2 Teresa Borrás,2 and Oscar A. Candia3
PURPOSE. To investigate whether intracameral injection of the
adenovirus vector AdhGRE.MMP1 would reduce or prevent
elevated intraocular pressure (IOP) induced by corticosteroids
in living animals.
METHODS. Glucocorticoid-inducible adenovirus vectors car-
rying wild-type or mutant forms of human metalloproteinase
1 (MMP1 and mutMMP1) cDNAs were generated. An adeno-
virus carrying no gene (Ad5.CMV.Null) was used as an ad-
ditional control. Sheep were injected intracamerally with 30
L of each vector, either previously or after the induction of
increased IOP with topical prednisolone or sub-Tenon tri-
amcinolone under various protocols. IOP was measured
with a Perkins tonometer. Inflammation was monitored by
visual inspection.
RESULTS. In eyes in which IOP was already elevated to 24 to 30
mm Hg, injection of AdhGRE.MMP1 reduced IOP by 70% in 24
hours and to 10 to 13 mm Hg in 48 hours. In eyes with normal
IOP (9–11 mm Hg), preinjection of the virus protected against
the increase in IOP normally produced by the corticosteroid.
IOP remained at a level of approximately 12 mm Hg for 5 days
despite the continuous application of the corticosteroid. Injec-
tions of the control viruses had no hypotensive effects. There
were no signs of ocular inflammation or discomfort to the
animals.
CONCLUSIONS. A single dose of a gene therapy vector carrying an
inducible metalloproteinase human gene can both protect
against the IOP increase produced by corticosteroid instillation
in the sheep model and quickly reverse the IOP increase
previously elicited by the corticosteroid. These results are a
first step toward a treatment of steroid-glaucoma with induc-
ible overexpression of extracellular matrix modulator genes.
(Invest Ophthalmol Vis Sci. 2010;51:3042–3048) DOI:10.1167/
iovs.09-4920
Glucocorticosteroids such as prednisolone exhibit thera-peutic versatility given their common use as anti-inflam-
matory, immunosuppressive, and antiangiogenic agents.1,2
However, glucocorticosteroids also elicit adverse ocular effects
such as cataract formation and increased IOP.3 Persons suscep-
tible to increased intraocular pressure (IOP) may require treat-
ment for glaucoma. The phenomenon of glucocorticosteroid-
induced ocular hypertension has been recognized for
decades,4 and a number of predisposing risk factors have been
identified among patients receiving various corticosteroid
treatments.5,6 Yet the mechanisms by which glucocorticoste-
roids induce IOP elevation have not been determined. It is
recognized that this adverse effect is the result of reduced
trabecular aqueous humor outflow associated with morpho-
logic and biochemical changes in the trabecular meshwork.5,6
As such, a thorough understanding of the cellular processes
eliciting corticosteroid-induced ocular hypertension may shed
light on the cause of primary open-angle glaucoma.
We recently demonstrated the effectiveness of using Cor-
riedale sheep (Ovis aries) as an animal model for glucocorti-
costeroid-induced ocular hypertension.7 The IOP of these ani-
mals increased 2.5-fold within 2 weeks of topical application
of 0.5% prednisolone acetate three times daily. This intraocular
pressure elevation occurred with a 100% incidence in the
corticosteroid-treated eyes. After the discontinuation of corti-
costeroid instillation, the IOP of the treated eyes declined to
baseline values over the course of 1 to 3 weeks. Similar IOP
elevations were obtained in all sheep receiving the corticoste-
roid triamcinolone acetonide, applied as a single sub-Tenon
injection rather than as a topical application (our unpublished
observations, 2009).
The 100% incidence of corticosteroid-induced ocular hyper-
tension in O. aries and the docile nature of the animals, which
readily submit to manipulations such as those required for in
vivo outflow facility measurements, render this species an ideal
model for both examining the mechanisms underlying cortico-
steroid-induced glaucoma and testing possible IOP-lowering
agents. In this work, we tested the newly developed glucocor-
ticoid-inducible matrix metalloproteinase 1 (MMP1) gene ther-
apy vector (see Ref. 8) for its ability to reduce corticosteroid-
induced ocular hypertension in the sheep model. We found
that a single dose of a gene therapy vector carrying an induc-
ible metalloproteinase human gene can protect against the
increase in IOP normally produced by corticosteroid instilla-
tion in the sheep model and can quickly reverse the IOP
increase elicited by corticosteroid pretreatments.
MATERIALS AND METHODS
Animals
All animal experiments were performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Eighteen healthy (female) sheep (Corriedale breed) between 12 and 24
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months of age, and weighing 35 to 40 kg each, were selected from a
local ranch in Corrientes, Argentina, for this study. The eyes and
general health of the animals were considered normal by an ophthal-
mologist and a veterinarian, respectively. Sheep were tagged for indi-
vidual identification on their ear lobes and herded from pasture when-
ever it was necessary to topically instill prednisolone, inject a sub-
Tenon depot of triamcinolone acetonide, inject adenoviral vectors
carrying the MMP1 transgene intracamerally by way of the cornea, or
measure IOP by applanation tonometry. To apply prednisolone, the
sheep were guided into a funnel corral ending in a loose-fitting yoke.7
This arrangement allowed one person to move the animal’s head and
hold it while another instilled the drops. To measure IOP with a
Perkins tonometer, the sheep were guided into the funnel corral and
then into the neck yoke. For sub-Tenon injection of triamcinolone and
the trans-corneal injections of adenoviral vectors, sheep were anesthe-
tized topically. Between all procedures, the sheep were free to pasture.
Prednisolone Instillation Protocol
In sheep eyes in which prednisolone was used to induce ocular
hypertension, the following general protocol was applied. After deter-
mining the baseline measurement of IOP over the course of several
days, two drops of 0.5% prednisolone acetate (Ultracortenol; Novartis
Ophthalmics, Hettlingen, Switzerland) was topically instilled three
times daily at 7 am, 2 pm, and 7 pm for durations that lasted for 10 to
15 days, depending on the experiment. In some experiments, pred-
nisolone was instilled bilaterally; in others, only one eye received the
corticosteroid.
Sub-Tenon Injection of Triamcinolone in
Topically Anesthetized Sheep Eyes
In those sheep in which triamcinolone was used to induce ocular
hypertension, the following general protocol was applied. Two drops
of proparacaine (0.5%) were topically instilled to the ocular surface.
Then a single 1-mL injection of sterile triamcinolone acetonide (40
mg/mL or 4%; Bristol-Myers Squibb, Princeton, NJ) was administered
by sub-Tenon injection using a 30-gauge needle inserted 5 mm from
the limbus.
For injections, the distance from the limbus was determined from
the width of a 5-mm  30-mm Schirmer strip that was held between
the limbus and the injection site. The conjunctiva at the injection site
was grasped with fine forceps, and an initial oblique conjunctival
puncture was made with the needle bevel facing upward. The needle
was then pushed deeper (continuing at an oblique angle) to create
another puncture in the Tenon capsule in such a manner that the
Tenon puncture did not underlie the conjunctival puncture. The nee-
dle was pushed through the Tenon capsule until the tip reached the
sclera (as determined by feel). Care was taken to avoid puncturing the
sclera itself. In addition, because the Tenon capsule consists of several
layers, care was taken to administer a sub-Tenon (to create a juxta-
scleral depot), not an intra-Tenon, injection. Immediately after the
injection the needle was rapidly withdrawn. The volume injected (1
mL) yielded a characteristic 180° to 240° quasi-donut-shaped bolus of
fluid around the limbus. Each injected eye then received 2 drops of
tobramycin ophthalmic solution (Tobrex 0.3%; Alcon Laboratories,
Inc., Forth Worth, TX).
Measurement of IOP of Conscious Sheep with the
Handheld Perkins Applanation Tonometer
Animals were led to a funnel corral, and their heads were suitably
oriented within a neck yoke to enable an ophthalmologist to measure
IOP with the Perkins tonometer. Before the IOP measurement, 2 drops
of topical 0.5% proparacaine (Alcon Argentina, Buenos Aires, Argen-
tina) followed by 2 drops of 0.25% fluorescein were instilled. Two sets
of measurements were taken on each eye, alternating first one eye and
then the other. All IOP measurements were taken between 2 pm and
4 pm every 2 or 3 days. Perkins tonometry readings were converted to
millimeters of mercury, as described in detail previously.7
Steroid-Inducible MMP1
Recombinant Adenoviruses
Details of the design, construction, characterization, and titration of
the steroid-inducible MMP1 adenoviruses are given in Spiga and Bor-
rás.8 Briefly, a full-coding MMP1 cDNA driven by a glucocorticoid-
response element (GRE) and a basal promoter was engineered into a
shuttle vector and electroporated into cells containing the adenovirus
genome. The transgene viral DNA was produced by recombination,
and the generation of the virus (AdhGRE.MMP1) was achieved by
transfecting the viral DNA into QBI-HEK-293 cells. As a functionally
negative control, an inducible vector carrying an MMP1 mutation in
the catalytic site (AdhGRE.mutMMP1) was constructed in a similar
manner. An additional control carrying no transgene (Ad5.CMV.Null)
was purchased from Qbiogen (Montreal, QC, Canada) and was grown
and purified in our laboratory. All recombinant adenoviruses were
grown and purified to high-titer stocks, as previously described.9 Viral
lots used in this study had concentrations of 3.1  1011 and 2.4  1011
virus genomes (vg)/mL (AdhGRE.MMP1), 4.0  1011 vg/mL (AdhGRE.
MMP1), and 9.3  1011 vg/mL (Ad5.CMV.Null), which correspond
approximately to twice the infectious units per milliliter (see Ref. 8).
Intraocular Injection of Adenoviral Vectors into
the Anterior Chambers of Sheep
Adenoviral vectors were constructed in the laboratory of TB (Univer-
sity of North Carolina, Chapel Hill, North Carolina) and were shipped
on dry ice to New York. OAC (Mount Sinai School of Medicine, New
York, NY) delivered the vectors to Corrientes for the experiments.
Until needed, the parcels containing the lots of viral vectors were
always maintained either on dry ice or in a freezer at 70°C. At the
time of viral administration, the appropriate Eppendorf tube contain-
ing the frozen virus suspension was thawed in the field as each sheep
was immobilized within a narrow passage ending in a yoke. Two drops
of topical proparacaine 0.5% (Alcon Argentina) were instilled on the
eyes as an anesthetic. After this,  30 L virus suspension was injected
into the eye using a Hamilton syringe with a 28-gauge needle. The
needles were inserted diagonally through the cornea (a few millimeters
inside the limbus) into the anterior chamber without touching the iris.
The injection procedure took less than 30 seconds.
Statistical Analysis
The significance of experimentally elicited changes in IOP were ana-
lyzed using Student’s t-test as either paired or unpaired data, with  
0.05 chosen as the level of significance. If both eyes from the same
animal react equally to a treatment, paired analysis can be used. On the
other hand, there is evidence that fellow eyes are not identical and in




The IOP in both eyes of the normal sheep used in this study
was measured before any treatment to establish the baseline
values. The measured Perkins tonometry readings and the
equivalent IOP as determined from a calibration curve indi-
cated baseline pressures between  9 and 11 mm Hg, values
similar to those obtained earlier.7
The present experiments were designed to determine
whether the intracameral administration of adenoviral vectors
carrying an active human MMP1 transgene could both prevent
IOP elevation in a sheep model of glucocorticosteroid-induced
ocular hypertension and reduce the elevation in IOP after its
establishment by pretreatments of corticosteroid. Prednisolone
was administered as one of the IOP-elevating agents, as used
previously.7 This corticosteroid was administered by thrice-
daily topical instillations. With this agent, IOP will remain
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elevated for as long as the instillation regimen is maintained.7
The second corticosteroid used in the present study was tri-
amcinolone, which was administered as a single sub-Tenon
injection. Its advantage is the less tedious application because
the agent is introduced only once, and subsequent daily ad-
ministrations are avoided. A disadvantage is that it is difficult to
accurately assess when the administered triamcinolone depot
has been depleted. In experiments described in this study, the
triamcinolone depots appeared to subsist for periods of 2 to
3 weeks, as determined by the IOP.
Hypotensive Effect of a Single Dose of
Glucocorticoid-Inducible MMP1 Adenovirus on
Prednisolone-Induced Ocular Hypertension
In the first set of experiments (Fig. 1), six normal sheep were
treated topically with prednisolone three times a day in both
eyes beginning on day 0. Subsequently, as IOP increased, one
eye of each sheep was injected with 1 of 3 adenoviral (Ad)
vectors. The active adenoviral vector (AdhGRE.MMP1) carried
the wild-type MMP1 transgene. MMP1 was chosen because it
encodes for a well-known trabecular meshwork (TM) enzyme
that breaks down extracellular matrix components. The other
two vectors (used as controls) included a null adenoviral vec-
tor (without transgene) (Ad5.CMV.Null) and a vector carrying
a mutated transgene with an inactive catalytic site (AdhGRE.
mutMMP1). These vectors also carried the inducible GRE ele-
ment so that transgene expression would be activated only in
the presence of steroids. Among the six sheep, two received
one of the three adenoviral vectors prepared. Three to 5 days
after adenoviral vector injection, elevated IOP was reduced in
eyes receiving the MMP1 transgene but not in either of the two
control eyes.
In the two eyes receiving the active MMP1 transgene (Figs.
1E, F), IOP returned to normal levels for at least 15 days. In one
sheep, IOP was monitored for 20 days (Fig. 1E); in the second
one, IOP was continuously monitored until day 27 (Fig. 1F). At
this point, IOP increased to a level identical with that of the
fellow eye not exposed to the adenoviral vector, suggesting
either that the induced MMP1 activity was transitory or that it
was overwhelmed by the continuous daily prednisolone appli-
cations.
No clinical adverse effects were noted in any of the eyes
treated with adenoviral vectors. There were no signs of con-
junctival hyperemia, inflammation, or irritation. Similarly, the
cornea remained clear without signs of edema in response to
viral injection. Presumably, the viral dose administered to the
sheep (5–6  109 vg, corresponding to approximately 2.5 to
3  109 infectious units) was not sufficient to trigger inflam-
mation in this species. Interestingly, a similar dose caused a
strong inflammatory response in cynomolgus monkeys,
FIGURE 1. (A–F) IOP measurements
in six sheep treated with adenoviral
vectors. Each graph represents data
from one animal. All animals were
treated with 2 drops of 0.5% pred-
nisolone acetate in both eyes starting
on day 0. Prednisolone instillation
continued three times daily until the
day indicated. Arrows: day the ani-
mals received a unilateral, intracam-
eral injection of an adenoviral (Ad)
vector; contralateral eyes were not
treated with viral vectors (unin-
jected). Two animals received a null
adenoviral vector (without trans-
gene; A, B), two received an adeno-
viral vector that carried a mutated
MMP1 transgene with out catalytic
activity (C, D), and two received an
active human MMP1 transgene (E,
F). One animal (E) was killed on day
20. Note that in the eyes that re-
ceived the active MMP1 transgene
(E, F), IOP returned to normal levels
for at least 15 days.
3044 Gerometta et al. IOVS, June 2010, Vol. 51, No. 6
whereas minimal or no signs of inflammatory reactions were
noted when the monkey was injected with 107 plaque-forming
units of adenoviral vectors.10
Hypotensive Effect of a Single Dose of
Glucocorticoid-Inducible MMP1 Adenovirus on
Triamcinolone-Induced Ocular Hypertension
Triamcinolone was used as the IOP-elevating agent in the
second set of experiments (Fig. 2). For this, four normal sheep
received bilateral sub-Tenon injections of triamcinolone on day
0, which caused the IOP to approximately double within 4
days. IOP increased from 11.0  0.3 to 22.6  0.8 mm Hg (n 
4) in the eyes to which adenoviral vectors carrying the mutated
MMP1 transgene were subsequently injected, and from 9.7 
0.2 to 22.1  0.2 mm Hg (n  4) in the eyes to which the
adenoviral vectors carrying the active MMP1 transgene were
subsequently injected (P  3  104, as paired data for these
IOP increases between days 0 and 4). After the IOP was
recorded on day 4, both eyes of each animal were injected with
the respective vectors. On days 6 and 7 (or 2 and 3 days after
the virus injections), IOP in the eyes receiving the active form
of the transgene were significantly lower than in fellow eyes
(P  2  105, as paired data). For example, on day 7, the IOP
of the eye injected with adenoviral vector with the mutated
form of MMP1 was 22.1  0.2 mm Hg (n  4), but in the fellow
eye receiving the active form it was 11.6  0.4 mm Hg (n  4).
Thereafter, the IOP of the latter eye increased to a level nearly
identical with that of the fellow eye by day 9 (P  0.15, as
paired data). The reason for this increase was not determined.
It is not clear why the apparent transitory MMP1 activity
persisted for at least 15 days in the experiments shown in
Figure 1 and for only 3 days in experiments shown in Figure 2.
In the experiments shown in Figure 2, the triamcinolone depot
appeared to be nearly consumed by day 18, as judged by the
IOP measurements. On this day, the IOP readings of the fellow
eyes were 10.5  0.4 mm Hg (n  4) and 12.4  0.2 mm Hg
(n  4).
In tandem with the experiments shown in Figure 2, three
other sheep were analyzed in parallel at the same time to check
the effect of injecting null adenoviral vectors (without trans-
gene) on the elevated IOP induced by triamcinolone (IOP plots
not shown). For this test, each sheep unilaterally received a
single sub-Tenon injection of triamcinolone on day 0. In two
sheep, injections were made in the right eye, but in the third
sheep, the injection was made in the left eye. On day 4, IOP
readings of the control eyes were 10.9  0.7 mm Hg (n  3)
and 25.2  0.4 mm Hg (n  3) in the eyes administered
triamcinolone (P  3  104, as either paired or unpaired
data). After these readings, the triamcinolone-treated eyes were
injected with null adenoviral vectors. Three days later, the IOP
readings were 9.4  0.0 mm Hg (n  3) and 23.1  0.4 (n 
3) for the control and steroid-treated eyes, respectively. The
IOP of the latter was significantly lower statistically (P  0.04,
as paired data) 3 days after receipt of the null adenoviral vector,
yet it was clear that the measured pressure difference was
meager and that IOP remained 2.5-fold higher than in the
control fellow eye. In contrast, in eyes receiving active MMP1
transgene, marked hypotensive effects can be measured within
24 hours of adenoviral vector injection, with reversions to the
baseline IOP within 2 to 3 days (Figs. 1, 2).
Protective Effect of a Single Dose of
Glucocorticoid-Inducible MMP1 Adenovirus
Injected before Triamcinolone Treatment
This protocol tested for preventive effects from pretreatments
with MMP1 transgene on the elevated IOP induced by the
triamcinolone depot. In these experiments, two sheep were
bilaterally injected with adenoviral vector carrying the active
transgene on day 0 and received sub-Tenon injections of tri-
amcinolone in both eyes on day 1 (Fig. 3). In these four eyes,
IOP remained near normal levels until at least day 5, at which
point IOP was 12.9  0.5 (n  4). The day 5 IOP value was
significantly higher than 9.4  0.1 mm Hg (n  4) measured on
day 0 (P  0.005, as paired data). At days 11 and 14, IOP
readings were 21.3  1.3 (n  4) and 19.1  1.0 (n  4),
respectively. These latter values were significantly higher than
values at day 5 (P  0.005, as paired data). The increase in IOP
between day 5 and day 14 occurred with a time frame within
which the triamcinolone depot likely subsisted. These results
suggest that the active transgene offered protection against
triamcinolone administration for at least 3 days. A protective
effect is evident because the injections of triamcinolone in the
control eye evoke a doubling of IOP within 4 days (Fig. 2).
Hypotensive Effects of a Single Dose of
Glucocorticoid-Inducible MMP1 Adenovirus on
Sheep Simultaneously Administered
Triamcinolone in One Eye and Prednisolone in
the Other Eye
Additional experiments (composed of two separate protocols,
each on one sheep) tested the effects of the injection of
adenoviral vector carrying active MMP1 transgene on the IOP
of contralateral eyes treated with unilateral triamcinolone and
unilateral prednisolone. In the first protocol of this set, one eye
of a sheep was administered triamcinolone by sub-Tenon in-
jection 2 weeks before the start of IOP measurements. The
point at which IOP measurements were initiated was desig-
nated day 0 of the experiment. The right eye, which received
the triamcinolone, exhibited an IOP about twice that of the left
eye (Fig. 4). After recording these measurements, thrice-daily
instillations of prednisolone were begun on the left eye. Three
days later, when the IOPs of both eyes were nearly identical,
adenoviral vector carrying the active MMP1 transgene was
FIGURE 2. IOP plot from four sheep treated with triamcinolone ace-
tonide and adenoviral vectors according to the following regimen.
Both eyes of each sheep received a single sub-Tenon injection of
triamcinolone on day 0. On day 4, one eye of each sheep received a
single intracameral injection of adenoviral vector that carried a mu-
tated MMP1 transgene without catalytic activity (closed symbols),
whereas the contralateral eye received adenoviral vector carrying an
active human MMP1 transgene (open symbols). Points are mean 
SEM of the four eyes receiving the mutated transgene and of the four
fellow eyes receiving the active transgene. In this set of experiments,
treatment with the active transgene reduced IOP to normal levels for
3 days. Ad, adenoviral vector.
IOVS, June 2010, Vol. 51, No. 6 Steroid-Hypertensive Sheep Treated with MMP1 Adenovirus 3045
bilaterally injected into the anterior chambers of the eyes.
Subsequently, IOP declined in tandem in the fellow eyes (Fig.
4). At the point of virus injection, the IOP of the right eye had
been elevated for 17 days; after virus injection, it was reduced
up to day 24. It is also possible that triamcinolone lost its
effectiveness, or that the depot was gradually depleted, be-
tween days 15 and 24 (Fig. 4). In the left eye, between days 15
and 24, IOP gradually increased, presumably because of a
diminished effect from the injected MMP1 transgene in the
face of continuous daily prednisolone instillations.
In the second protocol, the left eye of a sheep was injected
with adenoviral vector carrying the active transgene on day 0,
and the thrice-daily instillations of prednisolone were begun on
day 3 (Fig. 5). The contralateral right eye was pretreated with
a sub-Tenon injection of triamcinolone 2 weeks before the
initiation of IOP measurements. On day 0, IOP measurements
were initiated, and the right eye exhibited an IOP about twice
that of the left eye (Fig. 5), indicating a typical response to
corticosteroid administration. On day 1, the right eye was
injected with adenoviral vector carrying active MMP1 trans-
gene from the same lot as that given to the left eye; this
injection resulted in an ocular hypotensive effect within 24
hours in the right eye. Thereafter, the IOP of the right eye
remained low because of active protection from the MMP1
transgene or from a loss of effect of triamcinolone. The fellow
left eye appeared to have received a protective effect from the
MMP1 transgene administration up to at least day 15; thereaf-
ter, IOP gradually increased because of continuous pred-
nisolone instillations (Fig. 5).
DISCUSSION
Sheep are docile and compliant animals that are particularly
well suited for in vivo experiments such as those conducted in
the present study. This advantage outweighs the lack of exten-
sive genetic information on these animals. On the other hand,
ovine physiology appears similar to human and other primate
physiology with regard to aqueous secretion11 and trabecular
meshwork.12,13 The major advantage to using an ovine steroid-
FIGURE 3. Plots of the IOPs from two sheep treated with triamcino-
lone acetonide and adenoviral vectors according to the following
regimen. All eyes received vectors carrying the active transgene on day
0 and were administered a single sub-Tenon injection of triamcinolone
the next day. Top: individual IOP values from each eye. Bottom:
mean  SEM for the four eyes. Active transgene offered protection
against triamcinolone administration for at least 3 days.
FIGURE 4. Plot of the IOP from one sheep treated with triamcinolone
acetonide, prednisolone acetate, and adenoviral vectors according to
the following regimen. The right eye received a single sub-Tenon
injection of triamcinolone on day 14 (not shown). IOP measure-
ments began on day 0, at which point thrice-daily prednisolone instil-
lations were begun on the left eye. Both eyes received intracameral
injections of adenoviral vectors carrying active transgene on day 3.
FIGURE 5. Plot of the IOP from one sheep treated with triamcinolone
acetonide, prednisolone acetate, and adenoviral vectors according to
the following regimen. The right eye received a single sub-Tenon
injection of triamcinolone on day 14 (not shown). Adenoviral vectors
carrying the active transgene were injected intracamerally into the left
eye on day 0 and into the right eye on day 1. Prednisolone was
administered to the left eye during the days indicated.
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induced model of IOP elevation is the consistency and robust-
ness of the IOP response and its relatively low cost compared
with studies in primates. Moreover, the sheep model for cor-
ticosteroid-induced ocular hypertension was preferable to
other animal models. For example, only 50% of rabbits
treated chronically with glucocorticoids such as dexametha-
sone develop ocular hypertension; in fact, dexamethasone-
responding rabbits are commonly defined as those exhibiting
IOP elevations of at least 5 mm Hg.14 In contrast, all treated
sheep responded to prednisolone with 2.5-fold increases in
IOP, as reported previously,7 and sub-Tenon injection of a
triamcinolone depot was observed to be as effective as pred-
nisolone in elevating ovine IOP in that all sheep administered
triamcinolone exhibited ocular hypertension.
In the present study, triamcinolone was used for conve-
nience to avoid the necessity of applying prednisolone three
times daily as the sole method for elevating IOP in all proto-
cols. The triamcinolone acetonide preparation of the drug is
minimally water soluble and is injected into sub-Tenon’s space
as a suspension. In this form, the lowered water solubility
contributes to the formation of a relatively long-lasting depot,
from which drug delivery into the eye occurs through the
sclera.15,16 However, as discussed by Robinson et al.,17 many
studies have observed intrasubject variability in intraocular
drug levels after subconjunctival injection. These authors have
suggested that a number of factors may influence drug release
from the depot and intraocular entry, including differences in
conjunctival lymphatic and capillary blood flow, scleral thick-
ness, choroidal flow, and differences in the geometry of the
depot itself.17 Presumably, the complex release kinetics of
sub-Tenon triamcinolone might account for the varied degree
and duration of the IOP elevations that were obtained in our
protocols. For example, the IOP of the triamcinolone-treated
eye was higher than 25 mm Hg on day 15 in some experiments
(Figs. 4, 5), whereas an IOP lower than 20 mm Hg was ob-
served 15 days after sub-Tenon drug injection (Fig. 2). Never-
theless, we tested the MMP1 transgene at the plateau of the
elevated IOP to determine the potential usefulness of this
approach in reversing the induced ocular hypertension, which
was the central aim of this study.
Studies on cultured TM cells and on organ-cultured eyes, as
well as ultrastructural studies on human specimens, suggest
that the following general mechanisms may be involved in
glucocorticosteroid-induced ocular hypertension: mechanical
changes in the microstructure of the TM from the reorganiza-
tion of actin stress fibers and the formation of reversible actin
networks mediated by TM glucocorticoid receptors18,19; in-
crease in the deposition of extracellular matrix material alter-
ing the ultrastructure of the outflow pathway20–22; reduction
in the protease activities and phagocytic properties of the TM
cells, thereby decreasing the breakdown of substances in the
TM23–25; and reduction of water flow in the TM either trans-
cellularly or paracellularly.26,27
Gene expression profile analysis of human TM cells ex-
posed to prolonged dexamethasone treatment found that a
group of actins and actin-associated proteins are involved in
the development of cross-linked actin networks in the treated
cells.28 In addition, a trend toward decreased expression of
protease genes and increased expression of protease inhibitors
in the dexamethasone-exposed cells was identified.28
A role for proteases is also suggested by the results of the
present study. We determined that a single dose of a gene
therapy vector carrying an inducible human MMP1 gene could
both temporarily prevent the increase in IOP normally pro-
duced by glucocorticosteroid instillations in the sheep model
and reverse the IOP increase previously induced by the glu-
cocorticosteroids.
We did not observe cataract formation in any of the animals
used in this or our previous study on sheep7 or in unpublished
observations of sheep topically instilled prednisolone for 4
months. In the case of the triamcinolone depot, the drug
appeared to subsist in the eye for 14 to 20 days, as judged by
the IOP measurements.
Putatively, the triamcinolone depot might be a more effec-
tive experimental approach (compared with topical instilla-
tions) for elevating IOP because the drug is continuously
present in the eye until the depot is totally dissipated. In
contrast, there were 7- to 12-hour intervals between the ad-
ministrations of the prednisolone drops. This difference in
technique might explain the present observations that MMP1
activity induced by the adenoviral vector preparations seems to
have persisted for at least 15 days in the case of the pred-
nisolone experiments shown in Figure 1, and only 3 days in the
case of the triamcinolone experiments shown in Figure 2.
Additionally, the adenoviral vector preparations may not by
necessity be identical. Further study is needed to explain this
difference.
In short, our present work broaches the concept that it
might be possible to treat steroid glaucoma with an inducible
overexpression of extracellular matrix modulator genes. Given
the common characteristics between steroid glaucoma and
primary open-angle glaucoma, this potential therapy might
have general applicability.
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